Vincerx Pharma
VINCVINC · Stock Price
Historical price data
Overview
Vincerx Pharma is a NASDAQ-listed biotech (VINC) with a mission to address high unmet needs in oncology by developing novel therapeutics. The company employs a capital-efficient, virtual R&D model to in-license and advance a pipeline of targeted and immuno-oncology candidates. Its strategy centers on precise asset selection, biomarker-driven development, and exploring combination regimens to overcome therapeutic resistance. Despite facing significant financial and operational challenges common to early-stage biotechs, Vincerx aims to create value through disciplined pipeline progression and strategic partnerships.
Technology Platform
A flexible, asset-centric virtual R&D model focused on strategic in-licensing and development of novel oncology therapies, emphasizing biomarker-driven precision medicine and combination regimens.
Pipeline
4| Drug | Indication | Stage | Watch |
|---|---|---|---|
| VIP152 + BTKi | Relapsed Non Hodgkin Lymphoma | Phase 1 | |
| VIP152 (BAY 1251152) + VIP152 (BAY 1251152) 30 mg + Keytruda... | Neoplasms | Phase 1 | |
| VIP943 (QW) + VIP943 (BIW) | Acute Myeloid Leukemia | Phase 1 | |
| VIP236 (Q3W) + VIP236 (Q2W) | Neoplasms | Phase 1 |
Opportunities
Risk Factors
Competitive Landscape
Vincerx competes with large pharma and numerous biotechs in the crowded oncology space. Its differentiation lies in its agile, virtual operating model and experienced team's ability to identify and develop novel mechanisms, though it lacks the financial resources of its major competitors.